Impact of beta-blockers on cardiovascular outcomes in myocardial infarction patients with preserved or mildly reduced ejection fraction: Systematic review and meta-analysis of randomized trials.
Leonardo David Neira-Chunga, Diego Alexis Moncada-Gutiérrez, Gustavo Adolfo Vásquez-Tirado et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the impact of beta-blocker therapy on cardiovascular outcomes in 18,504 patients with acute myocardial infarction and preserved or mildly reduced left ventricular ejection fraction. The analysis found no significant reduction in the primary composite outcome (HR: 0.90; 95% CI: 0.81-1.01) for the overall population, although a subgroup with mildly reduced LVEF showed a potential benefit (HR: 0.82; 95% CI: 0.70-0.97).
Key findings
- Beta-blocker therapy did not significantly reduce the primary composite outcome in patients with LVEF ≥ 40% (HR: 0.90; 95% CI: 0.81-1.01).
- In patients with preserved LVEF, beta-blockers showed no significant effect on the primary composite outcome (HR: 0.94; 95% CI: 0.87-1.03).
- Patients with mildly reduced LVEF experienced a reduction in the primary composite outcome with beta-blocker therapy (HR: 0.82; 95% CI: 0.70-0.97).
Why it matters
Understanding the effects of beta-blockers on cardiovascular outcomes in myocardial infarction patients is crucial for optimizing treatment strategies, particularly in those with varying levels of left ventricular ejection fraction.